Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investors inject $11m into baldness therapy co

This article was originally published in Clinica

Executive Summary

Boston, Massachusetts start-up Follica has attracted $11m in series B financing to further the development of its treatment for androgenetic alopecia, the most common form of hair loss. The technology, which originated at the University of Pennsylvania, works by stimulating the growth of entirely new hair follicles, said the company. In conjunction with the financing, which was led by Polaris Venture Partners, Follica also announced several appointments. Former Genentech CEO Kirk Raab and principal of Polaris Dr Kevin Bitterman joins the board of directors; Scott Kellog, formerly of Sontra Medical, Ultracision and Ethicon Endosurgery, is now Follica's vice-president of operations; and Dr Stephen Prouty is promoted to vice-president of research.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel